미국 진단키트 업체 '퀴델 '2분기 실적 발표(2020.07.31)

2020.07.31

7월31일 퀴델의 주가는 282달러, 시총은 118.63억달러(원화 14조2356억원).

분석: 1분기 주당 순이익 0.93달러. 2분기 주당 순이익 1.86달러로

       퀴델의 연간 주당순이익은 7~8달러로 예상됨.

       현재가 기준 2020년 예상 PER는 35배~40배 사이로 추정.

       퀴델 시가 총액 14.2356조원은  씨젠 시총 6.8313조원(현재가 260,400원 기준)의  2.08배.

 

미국 진단키트업체인 퀴델은 2분기 매출 2.017억달러,영업이익 8453만달러, 순이익 6765만달러.

주당순이익 1.86달러로 발표. 1분기 주당순이익은 0.93달러.

시장예상치 1.12달러를 상회했고 작년 동기 실적은 0.36달러였다.

 

Quidel (QDEL) came out with quarterly earnings of $1.86 per share, beating the Zacks Consensus Estimate

of $1.12 per share.

This compares to earnings of $0.36 per share a year ago. These figures are adjusted for non-recurring items.

 

This quarterly report represents an earnings surprise of 66.07%. A quarter ago, it was expected that this medical diagnostics company would post earnings of $1 per share when it actually produced earnings of $1.22,

delivering a surprise of 22%.

 

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

 

Quidel, which belongs to the Zacks Medical - Products industry,

posted revenues of $201.75 million for the quarter ended June 2020, surpassing the Zacks Consensus Estimate by 0.18%. This compares to year-ago revenues of $108.25 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Quidel shares have added about 245.8% since the beginning of the year versus the S&P 500's gain of 0.9%.

What's Next for Quidel?

While Quidel has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Quidel was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.66 on $308.23 million in revenues for the coming quarter and $8.05 on $876.30 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

---------------------------------------------------------

https://finance.yahoo.com/news/quidel-qdel-outpaced-other-medical-153003135.html

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Quidel (QDEL) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

 

Quidel is a member of our Medical group, which includes 901 different companies and currently sits at #9 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

 

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. QDEL is currently sporting a Zacks Rank of #1 (Strong Buy).

 

Over the past 90 days, the Zacks Consensus Estimate for QDEL's full-year earnings has moved 42.45% higher.

This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

 

Based on the most recent data, QDEL has returned 231.64% so far this year.

Meanwhile, stocks in the Medical group have gained about 2.37% on average.

As we can see, Quidel is performing better than its sector in the calendar year.

퀴델은 올해 231% 상승했다.. 반면에 메디칼그룹의 다른 회사들의 평균 상승률은 2.37%이다.

 

To break things down more, QDEL belongs to the Medical - Products industry, a group that includes 81 individual companies and currently sits at #186 in the Zacks Industry Rank. On average, this group has lost an average of 3.24% so far this year, meaning that QDEL is performing better in terms of year-to-date returns.

 

Investors in the Medical sector will want to keep a close eye on QDEL as it attempts to continue its solid performance.